Key result
Bone marrow-derived mesenchymal stem cells prevented isoproterenol-induced myocardial hypertrophy in vitro and in vivo via synergistic vascular endothelial growth factor release.
Why the study?
Do bone marrow-derived mesenchymal stem cells prevent isoproterenol-induced myocardial hypertrophy in preclinical models?
Population
Neonatal rat ventricular cardiomyocytes in vitro and isoproterenol-induced hypertrophic hearts in vivo
Comparison
Bone marrow-derived mesenchymal stem cells via… vs Isoproterenol-induced hypertrophy without BMSCs
Design
Preclinical
Authors
Loading...
Should not alter clinical practice for hypertrophy; leaves open mesenchymal stem cell translation to human trials.
Do bone marrow-derived mesenchymal stem cells prevent isoproterenol-induced myocardial hypertrophy in preclinical models?
Crosstalk between mesenchymal stem cells and cardiomyocytes produces synergistic VEGF release, which inhibits pathological cardiac remodeling following hypertrophic stimulation.
Cai et al. (2015) studied Myocardial hypertrophy. Bone marrow-derived mesenchymal stem cells (BMSCs) was evaluated on Prevention of isoproterenol-induced hypertrophic characteristics of cardiomyocytes. Bone marrow-derived mesenchymal stem cells prevented isoproterenol-induced myocardial hypertrophy in vitro and in vivo via synergistic vascular endothelial growth factor release.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: